Adjudin 1-(2,4-二氯苄基)-1H-吲唑-3-碳酰肼

1-(2,4-Dichlorobenzyl)-1H-indazole-3-carbohydrazide
  1. 产品编号:sw21365
  2. CAS No.:252025-52-8
  3. 分子式:C15H12N4OCL2
  4. 分子量:335.18798
中文名称:1-(2,4-二氯苄基)-1H-吲唑-3-碳酰肼 AF-2364
CAS号:252025-52-8
中文别名:1-(2,4-二氯苄基)-1H-吲唑-3-碳酰肼;男用口服避孕药
英文名称:1-(2,4-Dichlorobenzyl)-1H-indazole-3-carbohydrazide
英文别名:1-(2,4-Dichlorobenzyl)-1H-indazole-3-carbohydrazide;AF-2364;Adjudin;1-[(2,4-Dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid hydrazide;AF 2364
EINEC:
分子式:C15H12N4OCL2
分子量:335.18798
生物活性  
靶点
Mitochondrial Metabolism
In vitro(体外研究)
Adjudin is a potent blocker of Cl- channels: disrupting Cl- ion transport function results in a decline in sperm capacitation and fertilizing ability in humans in vitro. Adjudin (ADD) is a mitochondria inhibitor. Adjudin is a molecule that mediates adherens junction disruption at the Sertoli-germ cell interface. To investigate the effect of Adjudin on cancer cells, more than ten different types of human or mice cancer cell lines are treated with increasing concentrations of Adjudin and the cell proliferation is measured by the modified MTT assay. Adjudin inhibits cell proliferation in a dose dependent manner in SGC-7901 (human gastric adenocarcinoma cell), MDA-MB-231 (human breast adenocarcinoma cell), Smmc-7721 (human hepatoma cell) and MIA Paca-2 (human pancreatic adenocarcinoma cell) cells. The IC50 of Adjudin is determined to be 58.0 µM, 13.8 µM, 72.3 µM and 52.7 µM against SGC-7901, MDA-MB-231, Smmc-7721 and MIA Paca-2 cells, respectively, after treatment for 24 h. Similar results are obtained in other human and mice cancer cell lines. The IC50 of Adjudin in A549 cells and PC3 cells is 63.1 µM and 93.0 µM, respectively. For WI-38 and BPH-1 cells, the IC50 of Adjudin can be observed at more than 300 µM and 200 µM, respectively, which is about 5 times and 2 times more than that for the cancer cell lines A549 and PC3.
In vivo(体内研究)
To determine whether Adjudin can inhibit lung and prostate cancer growth in vivo, the effect of Adjudin is tested in a subcutaneous model of lung and prostate cancer. Human lung carcinoma cells A549 and prostate carcinoma cells PC3 are injected into athymic nude mice subdermally at the lower back site respectively. Mice are then randomized into two treatment groups with similar mean tumor sizes: Adjudin and vehicle (control). Approximately 2 weeks after tumor inoculation Adjudin is injected intraperitoneally once every three days in lung carcinoma cells and every other day in prostate carcinoma cells at 100 mg/kg. Adjudin treatment can be well tolerated in rodent. And Adjudin-treated mice show significant tumor growth inhibition compared with the control group (P.


温馨提示:本产品仅作科研实验使用,不支持临床等研究

 
危险品级别:
HS符号:
危害声明: